Show simple item record

dc.contributor.authorArda-Pirincci, Pelin
dc.contributor.authorAykol-Celik, Guliz
dc.date.accessioned2021-03-05T17:37:06Z
dc.date.available2021-03-05T17:37:06Z
dc.date.issued2020
dc.identifier.citationArda-Pirincci P., Aykol-Celik G., "Galectin-1 reduces the severity of dextran sulfate sodium (DSS)-induced ulcerative colitis by suppressing inflammatory and oxidative stress response", BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, cilt.20, ss.319-328, 2020
dc.identifier.issn1512-8601
dc.identifier.otherav_c66d3973-47dc-4fb1-9b65-66c25c55566a
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/131555
dc.identifier.urihttps://doi.org/10.17305/bjbms.2019.4539
dc.description.abstractUlcerative colitis is an inflammatory bowel disease that affects a large number of people around the world. Galectin-1 is a beta-galactoside-binding lectin with a broad range of biological activities. The effects of galectin-1 on dextran sulfate sodium (DSS)-induced ulcerative colitis in vivo is not clear. We investigated the effect of galectin-1 on colon morphology, cell proliferation, oxidative stress, antioxidant system, and proinflammatory/antiinflammatory cytokines in a DSS-induced mouse model of ulcerative colitis. Thirty-two C57BL/6 mice were randomly assigned to one of the four groups: control, acute colitis, galectin-1, and DSS+galectin-1. Controls were treated with phosphate-buttered saline (PBS) for seven days. Acute colitis was induced by 3% DSS in drinking water administered orally for five days. Mice in galectin-1 groups were treated with 1 mg/kg recombinant human galectin-1 in PBS for seven consecutive days. Oral DSS administration resulted in acute colitis by causing histopathological changes; an increase in disease activity index (DAI), lipid peroxidation (malondialdehyde MDA]), myeloperoxidase (MPO), and tumor necrosis factor (TNF)-alpha levels; a decrease in body weight, colon length, cell proliferation index, catalase, glutathione peroxidase (GSH-Px) and superoxide dismutase (SOD) activities, and GSH and interleukin (IL)-10 levels. The treatment with galectin-1 attenuated DSSinduced acute colitis by reducing DAI, MDA, MPO, and TNF-alpha levels and by increasing body weight, colon length, cell proliferation, antioxidant enzyme activity, GSH, and IL-10 levels. These findings suggest that galectin-1 has proliferative, antioxidant, antiinflammatory, and cytoprotective effects against DSS-induced ulcerative colitis in mice. Due to its antiinflammatory and antioxidant activity galectin-1 may be effective in preventing and treating ulcerative colitis.
dc.language.isoeng
dc.subjectTıbbi Ekoloji ve Hidroklimatoloji
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectTIP, ARAŞTIRMA VE DENEYSEL
dc.titleGalectin-1 reduces the severity of dextran sulfate sodium (DSS)-induced ulcerative colitis by suppressing inflammatory and oxidative stress response
dc.typeMakale
dc.relation.journalBOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES
dc.contributor.departmentİstanbul Üniversitesi , Fen Fakültesi , Biyoloji Bölümü
dc.identifier.volume20
dc.identifier.issue3
dc.identifier.startpage319
dc.identifier.endpage328
dc.contributor.firstauthorID2275648


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record